Home | Our Specialities | Clinical Trials | Directions | Forms | Patient Portal

MS Center of Northeastern New York P.C.


In this section we have provided a list of publications and scientific articles authored by Dr. Edwards in the last five years.

For a complete list of Dr. Edwards' publications see below

Click here to download file

Articles in Multiple Sclerosis:


1. Cohen J, Calabresi P, Chakraborty S, Edwards K, Eickenhorst T , et. al, Avonex Combination Trial (ACT) in Relapsing-Remitting MS. Rationale, Design, and Baseline Data  Mult Scler  2008 Apr;14(3):370-382.


2. Phillips J, Weinstock-Guttman B, Felton W, Englis J, Rossman H, Edwards K, Honeycutt W, Sheremata W.  A Multicenter, Open-label, Crossover Study of Safety, Tolerability, and Patient preference for a Single-Use Autoinjector vs Manual Injection of Intramuscluar Interferon Beta-1a in Patients with Multiple Sclerosis.  Inter Jour of MS Care.: In Press


3. Cohen J, Imrey P, Calabresi P, Edwards K, Eickenhorst T, Felton III W, Fisher E, Fox R,Goodman A, Hara-Cleaver C, Hutton G, Mandell B, Scott T, Zang H,  Apperson-Hansen C, Beck G,  Houghtaling P, Karafa M, Stadtler M. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009: 72;535-541


4. Glantz M, Chamberlain M, Liu Q, Hsieh C, Edwards K, Horn A, Recht L. Gender disparity in the rate of partner abandonment in patients with serious medical illness. Cancer 2009:115;5237-42


5. Goodman A, Brown T, Edwards K, Krupp L, Schapiro R, Cohen R, Marinucci L, Blight A. A Confirmatory Phase 3 Trial of Sustained Release Oral Fampridine in Multiple Sclerosis. Annals of Neurology 2010;68:494-502


6. Nielsen S, Miravalle A, Langer-Gould A, Cooper J, Edwards K, Kinkel P. B cell depletion and safety of low dose rituximab in patients with relapsing multiple sclerosis. Multiple Sclerosis, 2012; 18: 277-378


7. Edwards K, Goodman W, Ma C. Improvement in neuropsycholological function in cognitively impaired multiple sclerosis patients treated with natalizumab. Int. Journal of MS Care; 14:100-104



Articles in Alzheimer and Dementia:


1. Edwards KR, Hershey L, WrayL, Bednarczyk EM, Lichter D, Johnson S.  Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies:  A 12-Week Interim Analysis.

Dementia and Geriatric Cognitive Disorders 2004:17 (suppl 1) 40-48.


2. Sadowsky C, Edwards KR, Etemad B, Falow M. Maintaining effective treatment in dementia: A case series on patients switched to rivastigmine. Primary Care Psychiatry 2004:9 71-75


3. Edwards KR, Koumaras B, Chen M, Gunay I, Mirski D.  Long-Term Effects of  Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing Home Patients with Alzheimer’s Disease: Results of a 52-Week Open-Label Study  Clinical Drug Investigation 2005: 25 507-515.


4. Grossberg G, Edwards K, Zhao Q.  Galantamine with Adjunctive memantine: Combined Effects on Brain Nicotinic Acetylcholine Receptors and N-methyl-D aspartate (NMDA) Receptors may Improve Alzheimer’s Disease Symptomatology  J. Clin. Pharmacol  2006 46: 17S - 26S.


5. Bhasin M,  Rowan E. Edwards K, McKeith IG.  Cholinesterase inhibitors in Dementia with Lewy Bodies – A comparative analysis.  Int J Ger Psychiatry  2007: 22; 890 – 895


6. Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M Pasquier F, Johnson S.  Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies:  A 24-Week Open Label Study.   Dem Ger Cog Dis. 23: 301-305, 2007


7. Connor G, Edwards K, Tarsy D.  Topiramate in Essential Tremor: Findings from Double-Blind, Placebo-Controlled, Crossover Trials. Clin Neuropharmacol  2008 Mar-Apr;31(2):97-103



MS Center of Northeastern New York, P.C. f/k/a Empire Neurology P.C
1182 Troy-Schenectady Road, Suite 203, Latham, NY 12110  
(518) 785-1000